
|Videos|October 28, 2022
Treatment of Late Relapse Multiple Myeloma with Belantamab Mafodotin
Shonali Midha, MD, highlights data from the DREAMM-5 study during her presentation on the use of belantamab mafodotin for late relapse multiple myeloma.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on CancerNetwork
1
EC Approves Encorafenib/Cetuximab/FOLFOX in 1L BRAF V600E–Mutant mCRC
2
Zanzalintinib/Atezolizumab Misses Survival End Point in Non-MSI-H mCRC Subgroup
3
Sigvotatug Vedotin Does Not Significantly Improve Survival in NSCLC Trial
4
NCCN Updates Bladder Cancer Guidelines for ctDNA MRD Testing
5






















































































